Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.
about
Industry Perspectives on Market Access of Innovative Drugs: The Relevance for Oncology DrugsDeveloping pharmacogenetic evidence throughout clinical development.Phase IV non-inferiority trials and additional claims of benefit.Access to orphan drugs despite poor quality of clinical evidence.Personalizing health care: feasibility and future implications.Response to Michael Wonder's comments on the article 'Assessment of the therapeutic value of new medicines marketed in Australia'Current european regulatory perspectives on insulin analoguesA Time-Trend Economic Analysis of Cancer Drug Trials.Fasting potentiates the anticancer activity of tyrosine kinase inhibitors by strengthening MAPK signaling inhibition.US Payer Perspectives on Evidence for Formulary Decision Making.A pilot randomized controlled trial comparing the efficacy of exercise, spinal manipulation, and neuro emotional technique for the treatment of pregnancy-related low back pain.UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACHA fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.Perceptions and factors affecting pharmaceutical market access: results from a literature review and survey of stakeholders in different settingsHow aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.The fiduciary obligation of the physician-researcher in phase IV trials.A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs.Assessment of the therapeutic value of new medicines marketed in AustraliaThe draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians.Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems.CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.The dilemma between efficacy as defined by regulatory bodies and effectiveness in clinical practice.Fasting plus tyrosine kinase inhibitors in cancer.Interactions between health technology assessment, coverage, and regulatory processes: emerging issues, goals, and opportunities.Assessing additional benefit in noninferiority trials.Standardized reporting for rapid relative effectiveness assessments of pharmaceuticals.A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer.Standardizing the Benefit-Risk Assessment of New Medicines
P2860
Q30383258-478A00C6-2836-4090-9276-5A63BBA79775Q33730146-22C97713-31B0-4F2D-8235-31E6CCFD97C9Q34747480-F64AD861-905A-4EE3-9743-F3DA72F435CFQ34829905-35D524F7-4138-47C6-AD08-AB8D549A92FBQ34938911-0582DB0C-FAD5-4B0E-BCBB-DA3B96CA3CA7Q35198442-59D364F8-4D8F-4897-9CF1-178075219BF1Q35574277-880FB8B2-AAED-4A88-BFA4-B94303A7138BQ35820527-FA4A50BE-B652-4336-B0B5-A1D526882A6BQ35828447-406A6038-61D1-4DA7-9E21-4FFCB7E12A3FQ35947781-2E7EB4DB-3293-4507-90AE-A8508772671AQ36524144-B31EBAC6-D53A-4359-B57A-3FA7AE1C2ECEQ36778700-777137D1-A485-4E82-B9C4-A58CF5014146Q37161896-8239D07F-6F9C-4415-A7A4-F0FD5F6A987EQ37293459-F836E730-AA34-477B-B5C4-1E160AEF68B9Q37474165-CB20381B-530C-488A-AD0E-9EFBC2456646Q37580151-EDB681E8-A494-48E5-A0BF-7CEAADEA150FQ37610459-B536D2A5-A0CA-462A-92ED-89DD846B7CE2Q37703341-7BE94ADE-5E4F-41F9-8B01-C63104882437Q37935697-662015B9-6E36-4A55-B7BD-7C0E3931AD64Q38131545-40750B3A-1717-4827-996E-99AA6BC32E8CQ38380750-DFC26EA1-AFBE-49C5-9478-45926FE02EA6Q38492748-6ED589FB-6CAB-4B3A-B45F-A2F81346B99AQ38808261-8554371C-78EB-4D4E-8B2F-E99EDF8F6098Q39041221-E9341CA3-818E-4C66-9D46-CE1B45B8BBABQ39537209-8CE0855A-5756-4F2A-AD6B-10205DCE38C6Q42584598-EEEC14F1-ECAC-4388-B074-AB0EF63C5E58Q43089290-D6B69874-36A6-4470-82DF-E122B9D9D18EQ43436188-1FE6F632-6C53-4F74-A1B8-A058411CDAE9Q48263630-1626E784-6579-4AC3-ABAC-630CF889AD1CQ48531778-713DEDF3-036D-4038-AFA3-9BF400586235Q53001245-1C595CFF-3C4C-4088-9ED2-B820BF31B3CDQ55934009-FCC42190-EB0E-4C79-8450-BBD057B23626
P2860
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Relative efficacy of drugs: an ...... encies and third-party payers.
@en
Relative efficacy of drugs: an ...... encies and third-party payers.
@nl
type
label
Relative efficacy of drugs: an ...... encies and third-party payers.
@en
Relative efficacy of drugs: an ...... encies and third-party payers.
@nl
prefLabel
Relative efficacy of drugs: an ...... encies and third-party payers.
@en
Relative efficacy of drugs: an ...... encies and third-party payers.
@nl
P2093
P2860
P356
P1476
Relative efficacy of drugs: an ...... encies and third-party payers.
@en
P2093
Brigitte Bloechl-Daum
David Barnett
Eric Abadie
Hans-Georg Eichler
Steven Pearson
P2860
P2888
P304
P356
10.1038/NRD3079
P50
P577
2010-02-26T00:00:00Z